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Abstract A randomized controlled efficacy trial targeting older adults with hyperten-
sion (age 60 and over) provided an e-health, tailored intervention with the “next
generation” of the Personal Education Program (PEP-NG). Eleven primary care
practices with advanced practice registered nurse (APRN) providers participated.
Participants (N=160) were randomly assigned by the PEP-NG (accessed via a wireless
touchscreen tablet computer) to either control (entailing data collection and four
routine APRN visits) or tailored intervention (involving PEP-NG intervention and four
focused APRN visits) group. Compared to patients in the control group, patients
receiving the PEP-NG e-health intervention achieved significant increases in both self-
medication knowledge and self-efficacy measures, with large effect sizes. Among
patients not at BP targets upon entry to the study, therapy intensification in controls
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(increased antihypertensive dose and/or an additional antihypertensive) was significant
(p=.001) with an odds ratio of 21.27 in the control compared to the intervention
group. Among patients not at BP targets on visit 1, there was a significant declining
linear trend in proportion of the intervention group taking NSAIDs 21–31 days/month
(p=0.008). Satisfaction with the PEP-NG and the APRN provider relationship was
high in both groups. These results suggest that the PEP-NG e-health intervention in
primary care practices is effective in increasing knowledge and self-efficacy, as well as
improving behavior regarding adverse self-medication practices among older adults
with hypertension.
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Objectives
According to the World Health Organization, hypertension represents the greatest risk
factor for premature death worldwide (Mathers et al. 2009). More than one-third of
adults aged 60 and over in the United States has hypertension—a condition resulting
in more health care visits than any other chronic condition (Schroeder et al. 2004).
Nationwide, it is estimated that only 35% of older adults with hypertension maintain
target blood pressure (BP) readings (<140/90; <130/80 for those with diabetes or
chronic kidney disease) (Schroeder et al. 2004; Wong et al. 2007). Inadequately
controlled hypertension, owing to poor patient adherence to antihypertensive
regimens and adverse-self medication behaviors, contribute to annual estimated
health care costs of $100 billion (Institute of Medicine 2006; NHLBI 2007).
Older adults with hypertension were found to have low self-efficacy in their ability to
avoid serious health consequences, owing to their large knowledge deficits regarding
interactions between prescription and OTC agents (Neafsey and Shellman 2002a).
Rather than identify and remediate low self-efficacy in patients, which results in poor
adherence and adverse self-medication behaviors, uncontrolled BP is often treated
with intensified antihypertensive therapy. This therapy is regularly administered with
increased doses, additional agents, and/or drug changes, thus further heightening the
risk of adverse drug effects (ADEs) and patient care costs (Ho et al. 2008; Peterson
2008). Moreover, clinical trials have yet to demonstrate any long-term improvement in
patient adherence to antihypertensive therapy (Haynes et al. 2008). By contrast,
intensive, monthly counseling by nurses or pharmacists has been shown to improve
antihypertensive adherence in older adults, but BP control typically declined when the
intervention ceased (Bosworth et al. 2005; Lee et al. 2006; Roumie et al. 2006).
There are a number of other causes and/or effects related to unsuccessful control
of patient blood pressure level. For instance, patient reticence about reporting
symptoms from medication side effects during provider visits is significantly
correlated to ameliorable and preventable adverse drug events (ADEs) (Weingart et
al. 2005). The number of symptoms reported during the past month is associated
with the number of self-reported ADEs (Oladimeji et al. 2008). Over-the-counter
(OTC) medications, supplements, and alcohol all interact with antihypertensives and
contribute to poor BP control (Gurwitz et al. 2003; Institute of Medicine 2006;
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Wallsten et al. 1995). For example, patients with hypertension may choose a non-
steroidal anti-inflammatory drug (NSAID) to self-medicate pain (Neafsey and
Shellman 2001; Neafsey et al. 2007)—without knowing that NSAIDS (e.g.
ibuprofen) can increase blood pressure and antagonize the anti-platelet effects of
low-dose aspirin and the effects of anti-hypertensive agents when taken concurrently
(Aw et al. 2005; MacDonald and Wei 2003; Polonia 1997). Hence, it seems logical
to find that educating patients about safe medication use can help reduce the risk of
potential adverse drug interactions (PADI) (Gurwitz et al. 2003).
With advances in e-health, a tailored system could provide a cost-effective patient
education tool to help increase patient knowledge and self-efficacy, and thus safe
self-medication practice. The Personal Education Program (PEP) is one such
network-based e-health intervention system that has demonstrated its effectiveness in
improving safe self-medication knowledge, efficacy, and behaviors among older
adults with hypertension (Neafsey et al. 2002, 2001; Strickler and Neafsey 2002). Its
successor, the “next generation” PEP (PEP-NG), contains significant software and
educational content enhancements. For instance, the once paper-and-pencil mea-
surement instruments (assessing such outcome measures as medication use,
medication knowledge, self efficacy, and user satisfaction) became part of the
software system to enable dynamic real-time assessment of patient interface
outcomes. A rules engine was added to the software system to assess self-reported
self-medication behaviors and deliver tailored education to the patient.
Thismanuscript presents the results of an efficacy trial of the PEP-NG conducted in 11
primary care settings. The tailored, touch-screen tablet-based educational intervention is
one of the first designed to reduce adverse self-medication behaviors in older patients
with hypertension. In conceptualizing the study, which aimed at stimulating cognitive
learning and enhancing self efficacy in patients to motivate them to adopt safe self-
medication practices and modify adverse self-medication behaviors, Bandura’s social
cognitive theory was utilized as the general theoretical framework to guide the study
design (Bandura 1997, 2001). The constructs of Bandura’s Social Cognitive Theory
(following, in quotes, Bandura 2001), as applied to the PEP-NG content design,
encompass the following conceptual aspects: 1) “symbolizing capability” (animations in
the PEP-NG formmental pictures) that give “meaning, form, contiguity” to patients’ self-
medication experiences to “guide future behaviors;” 2) “vicarious capability” (anima-
tions and related multiple choice questions) that enables “observational learning” so that
patients can envision patterns of behavior quickly, avoiding mistakes; 3) “forethought
capability” (interactive questions in the tailored-education segments) that allow patients
to consider “predictive function and expectations of behavioral outcomes;” 4) “self-
regulatory capability” (self-efficacy instrument and feedback from interactive questions)
that motivates patients to acknowledge their confidence in performing future tasks related
to self-medication; and 5) “reciprocal determinism” that enables the “bi-directional
interaction” with the APRN during the focused visit following PEP-NG use.
The goal of the clinical efficacy trial (conducted in primary care settings) was to
reduce adverse outcomes associated with unsafe self-medication practices in older
adults with hypertension – through improved patient-provider communication—with
the aid of the PEP-NG system. Trial objectives for older-adult patients were to show
that users of the PEP-NG would: 1) increase knowledge concerning potential drug
interactions stemming from unsafe self-medication practices; 2) enhance their self-
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efficacy in learning and adopting safe self-medication practices; 3) reduce self-
reported unsafe self-medication behaviors associated with potential adverse drug
interactions; 4) improve their prescription medication adherence; 5) achieve and
maintain target blood pressure readings; 6) express their satisfaction with the PEP-
NG; and 7) enhance the patient-APRN provider relationship.
Methods
A full description of the PEP-NG instruments, interface, prior usability, pilot testing
with older adults, and clinical-trial methodology can be found elsewhere (Lin et al.
2009, 2010; Neafsey et al. 2009, 2008; Strickler et al. 2008). A brief explanation of
how the patient and provider utilize the PEP-NG software to achieve the study
objectives is provided below, followed by a description of the research procedures
adopted for the current project.
PEP-NG Interface
The PEP-NG was accessed via a wireless tablet computer*; patients used a stylus to
answer questions on the touchscreen interface. In terms of on-screen display, visual
objects were large (3 cm high) and text size was in a 20-point size Arial Black font to
facilitate ease of reading for older adults. Ergonomically adaptive, wide-scroll bars and
dropdown-menus displayed in blocks of eight lines eased selection of agents for those
with impaired hand mobility and/or fine tremor. The time of medication and dosage was
reported with the use of an easy-to-use animated clock. Patients were asked what they
took for treating common ailments or conditions (e. g. blood pressure, blood thinning,
pain, cold or sinus, allergies, sleep, stomach problems such as indigestion or gas, and low
thyroid). Patients were also asked, “Did you take ____ in the last month?”with respect to
calcium pills, vitamins, minerals, herbs or supplements, and alcohol, wine, or liquor.
A rules engine analyzed patient-inputted information and immediately delivered
individually tailored educational content on the tablet screen. Summaries of a
patient’s self-reported symptoms, medication use (including frequency/time),
adverse self-medication behaviors (along with a thumbnail screen shot from a
related animation), and corrective strategies were automatically printed for review by
the APRN provider prior to the primary care visit. The APRN reinforced the
corrective education information (that appeared on the printout) with the patient as
part of their primary care BP visit. At the conclusion of the APRN visit, the patient
took a copy of the same printout home for self-study. A Virtual-Private-Network
(VPN) transferred all PEP-NG interface data to a Microsoft Access database. The
VPN met HIPAA requirements (Federal Register 2000) and the European Union
Directive 95/46/EC (de Meyer et al. 1998). The interface was developed in
accordance with ISO 9100 international standards (ISO 2004; Kelly 2000).
Participant Recruitment
The study was approved by the University Institutional Review Board (IRB) and met all
HIPAA regulations prior to enrolling any provider or patient participants. All methods
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adopted were performed in accordance with the 1964Declaration of Helsinki and all study
participants gave consent prior to participation in the study (World Medical Association
1964). Two practice-based research networks (PBRN) in New England cooperated in
study site recruitment. APRNet is a PBRN of APRNs, funded by the Agency for
Healthcare Research and Quality (AHRQ) and administered by the Yale School of
Nursing. The Connecticut Center for Primary Care (CCPC) PBRN is an independent,
non-profit corporation established (under CT law) by ProHealth Physicians, Inc.
Primary-care practice owners and APRNs affiliated with each PBRN were sent an
illustrated brochure describing the study and inviting them to participate. A member of
the research team gave an on-site demonstration of the PEP-NG software and study
materials to APRNs interested in participating in the study. Once recruited, practices
were offered free installation of a wireless-access node (meeting HIPAA requirements)
and a free tablet computer (in addition to the unit used for the study) as incentives for
participation. APRNs were offered $80 to compensate for their completion of the 2-h,
on-site PEP-NG study training. They were also offered 10 continuing education units
(CEUs) for reading 10 journal articles (related to potential adverse effects caused by
unsafe patient self-medication behaviors) and subsequently completing the pre- and
post-training instruments. APRNs (or the primary care practices) were also offered
$55 for each participant enrolled (up to 24 participants). This payment was to
compensate for the approximately 40 min of time needed to ascertain study eligibility,
conduct the informed consent process, show the online tutorial to the patient, keep the
participant gift-card receipts, and file recruitment reports for each patient participant.
Practices associated with the PBRN networks entered the study in an ongoing
basis. A member of the research team who was in a post-masters’ adult nurse
practitioner program conducted the 2-h on-site training session with each APRN.
Each APRN was given a research notebook with a step-by-step study protocol,
instruments for assessing study eligibility, record sheets for documenting each visit,
grocery gift cards, and study appointment cards. Illustrated participant recruitment
brochures and posters with the APRNs’ names and practice contact information were
placed in waiting and examination rooms. Older adults self-referred for the study by
calling the practice and making an appointment with the APRN. The APRN met
with each prospective participant to review the consent form (written in an Arial 14
font at a grade-6 reading level). Participants were requested not to participate in
another research study related to their health while enrolled in the PEP-NG study.
After attaining patient consent to participate, the APRNs used the following
inclusion criteria to assess study eligibility: 1) not previously involved in a PEP
study; 2) at least age 60 (by self-report); 3) a health literacy score of at least 44 (6th
grade) as measured by the Rapid Estimate of Adult Literacy in Medicine (REALM)
tool (Davis et al. 1993, 1998); 4) currently taking prescribed antihypertensive
medication; and 5) independent-living and cognitive-functioning ability. The latter
was reflected by the older adult’s ability to: a) independently manage the tasks of
telephone communication, shopping, travel arrangements, self-medicating, and
finance activities, as assessed with the Instrumental Activities of Daily Living
Scale, (Lawton and Brody 1969); b) successfully answer 6 of 10 items on the Short
Portable Mental Status Questionnaire, (Pfeiffer 1974); and c) live independently.
Eligible patient participants also needed to demonstrate a visual acuity of at least 20/100
(with corrective lenses, if needed).
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APRNs selected a four-digit random number from a list (provided by the study) as
the log-in ID for each participant. The APRN also selected a random number for the
APRN log-in ID and another for the site ID. In order to minimize confounding
effects due to the heterogeneity among APRNs and site-patient populations, the
PEP-NG randomly assigned participants within each site to either the control or
intervention groups. APRNs mailed the PI monthly monitoring reports with the
numbers of patients, using the following metrics: a) screened for participation; b)
met and not met study criteria; c) enrolled; d) dropped out of the study; and e)
experienced adverse or unexpected effects such as anxiety or eye strain. APRNs
were also asked to immediately report any adverse events to the PI.
APRN Training
Before the on-site training, APRNs logged on to a dedicated website to complete
pre-training Rx-OTC knowledge, Rx-OTC self-efficacy, and Eldercare self-efficacy
instruments. During the training session, APRNs tested the separate patient and
provider interfaces of the PEP-NG. They were also given a packet of 10 articles,
written by the PI, documenting the evidence that underlies the specific adverse
medication behaviors addressed by the PEP-NG. After reading these articles (over
the next 2 weeks), the APRNs logged on to an APRN-dedicated website to complete
post-training knowledge and self-efficacy measurement instruments. The APRNs
completed the post-training instruments at two different times—after successfully
enrolling their sixth participant (typically 3 months later) and their twelfth participant
(typically 6 months later), respectively.
Trial Protocol
Participants met individually with their APRN four times over 3 months in a private
examination room at the practice site. Participants were encouraged to bring all of
their medications (including supplements) to each visit. The APRN took the patient’s
BP at the beginning of visit 1. By attaching a keyboard to the tablet, the APRN
entered the participant’s year of birth (confirmed from the medical record), gender,
BP, and REALM health literacy score (Davis et al. 1993, 1998) via the tailored
APRN-provider interface. The APRN also entered each patient’s prescribed and
provider-recommended (e.g. low-dose aspirin) medications, including, dose, timing,
and any special instructions for taking the medication.
Upon completion of patient data entry, the APRN removed the tablet from the
keyboard and set it on a height/angle adjustable stand to ready the tablet for patient-
participant use. The APRN read a tutorial script to the participant, while the
participant practiced using a stylus to touch the interface and sample screens
(including a question, a medication screen, a “clock” screen, and an interactive
animation screen). When the participant expressed comfort with the patient interface,
the APRN left the patient to begin the PEP-NG interface task independently.
On visit 1, participants completed demographic questions concerning living
environment (with whom they live, type of residence), education, race/ethnicity,
income (e.g. whether their monthly income is at, above, or below $1,500 per month),
as well as health questions about current medical problems and symptoms. The
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patient then completed all measurement items (except the satisfaction survey) and
responded to questions about the medications and OTC agents they take for treating
their blood pressure and common health problems. On visits 2–4, before asking the
patient to continue with the PEP-NG unassisted, the APRN reviewed patient comfort
with the stylus use and PEP-NG interface as needed. Demographic questions were
omitted on visits 2–4. On visit 4, participants completed the patient-satisfaction
instrument, in addition to the other scales and questions measured during visits 1–3.
After each PEP-NG use, the participant visited with the APRN for approximately
15 min. During the visit, the APRN took the participant’s BP, based on the JNC-7
standards (Chobanian et al. 2003). The APRN then recorded the BP reading and
reviewed/updated any changes in the medication regimen on the provider interface.
Participants in the intervention group received tailored education in the following
manner. The PEP-NG rules engine analyzed patient-entered information and
delivered educational content tailored to the three patient-reported behaviors
associated with the highest risk scores. The education components included: 1)
animations and “medicine facts” that illustrated and described the adverse behaviors
identified; 2) “what you can do” tips which offered corrective strategies; and 3)
interactive questions that allowed the user to rehearse and apply the information
learned. A printout generated by the patient-reported data on the PEP-NG listed
patient-reported symptoms, the three identified adverse self-medication behaviors
and corrective strategies suggested by the PEP-NG, along with thumbnail screen
shots from the animations. In the case of fewer than three reported adverse
behaviors, the PEP delivered a set of up to three default statements dealing with
medication adherence, OTC pain relievers (that can be safely taken with
antihypertensives), and dangers of combining different types of pain relievers
(prescription and OTC). A copy of the printout was also given to the APRN to help
inform the patient visit as described above.
Like their counterparts in the intervention group, participants in the control group
were asked to complete all questions via the PEP-NG. They also received a general
education message, an interactive animation, and an interactive question at the end
of each session, which highlights how BP medicines work and emphasizes how BP
medications must be taken every day. These participants did not receive a printout at
the end of each of their PEP-NG uses or APRN visits.
Participants in both the intervention and control groups were offered a $10
grocery gift card at the end of each of the first three visits and a $25 grocery gift card
at the end of the fourth visit to compensate for time in the study. At the end of the
fourth visit, the patient was given a card with a dedicated telephone number to call—
if he or she wished to schedule a 20-min qualitative follow-up interview to be
conducted at the practice with a nurse researcher. The patient was given an
additional $10 grocery gift card for participating in the post-trial interview. The
APRNs were also invited to participate in the post-study interview and given a $25
grocery gift card as reimbursement for their time.
Outcome Measures
The Adverse Self-medication Behavior Risk, OTC-Rx Knowledge, OTC-Rx Self-
Efficacy, Eldercare Self-Efficacy, and Healthcare Relationships and Satisfaction
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Scales were previously validated, along with a description of their individual
psychometric properties (Anderson and Spencer 2002; Neafsey 1997; Neafsey and
Shellman 2002a, b; Neafsey et al. 2002, 2001, 2009; Shellman 2006). All
instruments were written at a 6th-grade Flesch-Kincaid reading level (Flesch
1968). The primary-patient outcome measure was patient Adverse Self-Medication
Behavior Risk Score. BP control, OTC-Rx Knowledge, OTC-Rx self-efficacy, and
health care relationships and satisfaction with the PEP-NG were secondary outcome
measures for patient participants.
BP measurements were taken by the APRN at each visit—at the beginning of PEP
use on visit 1, and post-PEP use on subsequent visits. Inadequate BP control was
defined as: 1) a SBP ≥ 140mmHg or a DBP ≥ 90 mmHg for patients without diabetes;
and 2) a SBP ≥ 130 mmHg or a DBP ≥ 80 mmHg for patients with diabetes or chronic
kidney disease, per the JNC-7 guidelines (Chobanian et al. 2003).
Adverse self-medication behaviors were identified from questions that address
use of medications (in the past month) to treat high blood pressure as well as use of
OTC agents and alcohol for problems that were self-treated with non-prescription
agents (e.g. pain, fever, colds or sinus, allergies, sleep, indigestion, gas,
constipation). Participants were also asked if they drank alcoholic beverages,
smoked or used nicotine, or took any vitamin or mineral supplements (including
what, when and how frequently each was taken). The Adverse Self-Medication
Behavior Risk Score is the weighted sum of the scores for the adverse behaviors
identified (Neafsey et al. 2009).
The OTC-Rx Knowledge scale has 14 multiple-choice items and the score is the
percent of the items with correct response; these items test both knowledge and
application concerning potential adverse effects of self-medication with OTC
agents, supplements, or alcohol in persons with hypertension. The OTC-Rx Self-
efficacy scale is a 12-item instrument with statements reflecting patient confidence
in selecting appropriate OTC agents and supplements, aside from avoiding adverse
effects arising from self-medication behaviors. This scale has 5-point self-report
response categories (ranging from 1, “Not Sure” to 5, “Totally Sure”). Responses
were summed and divided by the number of items answered, so that the overall
score would not be affected by omitted items and was reported based on the
original 5-point metric.
The Eldercare Self-Efficacy instrument is a 7-item, 5-point Likert-type scale that
assesses APRN self-efficacy in communicating with older adults about their
medications (Shellman 2006; Neafsey et al. 2009). The Health Care Relationships
Instrument is a 5-item instrument for patients, gauged with a 5-point Likert-type
scale (ranging from “not at all easy” to “very easy”) that measures patient-provider
communication (two questions), trust in provider, participation in decision-making
related to care, and satisfaction with care (Anderson and Spencer 2002).
The PEP-NG user Satisfaction scale is a 14-item instrument—with eight items
addressing the ease of program use, program content, and suitability of program
content—and another six items addressing the intent to change behavior following
program use. Ratings reflected by the 5-point Likert-type scale (ranging from 1,
“strongly disagree” to 5, “strongly agree”) were summed and divided by the number
of items answered to ensure that the overall Satisfaction scale was not affected by
omitted items and was cast in the original 5-point metric.
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Data Analysis
A complete description of the methods of data analysis and statistical power
considerations are published elsewhere (Neafsey et al. 2009). The study design
involved three factors: PEP-NG intervention vs. control, time (evaluation at baseline
and at three subsequent time points), and APRN (10 advanced practice nurses).
Variation in outcome measures between APRN, while likely to occur, was of
secondary interest, therefore the APRN factor was treated merely as a source of
random effects in statistical modeling and hypothesis testing. The principal study
hypothesis concerned the possibility of differential change in the PEP-NG and
control conditions between baseline and final study assessments. Although changes
could be contrasted between the PEP-NG and control groups for many outcome
measures, the comparison of changes in adverse self-medication risk score was of
primary interest. Statistical power analysis showed that a total sample of 164
subjects (82 per group) would be sufficient to yield 80% power to detect a 5-point
difference between the intervention and control groups in mean changes from
baseline to visit 4 in the adverse self-medication risk score.
Repeated measures linear-mixed model ANOVAmethodology was the basis of most
statistical tests and effect estimations. There are three reasons why this more complex
analysis tool was used instead of the simpler traditional least-squares ANOVA
technique. First, each participant was measured repeatedly over time (at each of four
visits); these four repeated measures are likely to be dependent, and therefore an
appropriate covariance-structure must be selected to capture this feature of the data.
Unlike traditional ANOVA, with mixed-model ANOVA it is no longer necessary to
assume the covariance structure adheres to compound symmetry or sphericity; instead,
one can choose from a large collection of covariance-structures as appropriate to the
observed data. Second, patients who visit the same APRN might tend to have similar
demographics characteristics, while patients across APRNs might tend to have different
characteristics. Such clustering effects need to be adjusted through the estimation of
random effects associated with the APRNs. Third, traditional linear model techniques
drop an entire participant from the analysis if the subject has missing data at one visit,
while linear mixed models allow subjects to have missing visit values. Hence, linear
mixed models provide researchers with a powerful and flexible analytic tool for these
kinds of data. The SAS software package (v. 9.2; SAS Institute, Inc., Cary, NC) allows a
full implementation of this analytical tool through its Proc Mixed procedure (Brown and
Prescott 2006; Verbeke and Molenberghs 2000; West et al. 2006).
The linear mixed models used study group (intervention vs. control) and visit (1–4) as
categorical variables and controlled for gender, age, APRN, income, education, and
computer use. Adjustment for computer use was performed because this variable was
significantly different between study groups at visit 1. Initially, the models considered the
possibility of an interaction effect between study group and visit on outcome measures.
However, whenever this interaction was not found to be significant, it was dropped from
the model. The potential impact of co-linearity between the income and education
covariates was considered before identifying the final model for each outcome measure.
Paired-t tests were used for post hoc analyses of knowledge, self-efficacy, and BP
within groups. Non-parametric tests (Cochran-Mantel-Haenszel statistic), based on
rank scores, controlling for participant code were used for the transformed behavior
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risk scores within groups. As age is significantly inversely correlated with DBP
(Chobanian et al. 2003), correlations between outcome measures were conducted
while controlling for age. Cross-tabulations comparing the frequencies of dichoto-
mous assessments relative to study group were created and subjected to statistical
testing through either the Pearson chi-square test or Fisher’s exact test.
Results
Fifteen provider practices and 20 APRNs consented to the study. Five practices and
five APRNs withdrew soon after the installation of the wireless access nodes for
reasons unrelated to the study (including APRN illness, APRN job change, and
practice-location change).
APRN Outcomes
Fifteen APRNs enrolled in the study and completed training. Three APRNS
withdrew from the study after training and before patient enrollment; two of them for
other jobs and one due to illness. An additional APRN withdrew after enrolling one
participant (who did complete the four visits). The patient data from this APRN were
removed from the analyses. The primary care practices had widely different patient
demographics and practice characteristics. The participating practices were located
in two urban centers, three small cities, two suburbs, and two rural areas. Eight of
the APRNs were salaried, two were paid by the number of patients seen, and two
were paid by the hour. All of the APRNs were Caucasian, with a mean age of 44.54
(9.71) (range 31–60 years). Themean APRN practice years was 8.4 (6.67) (range 1–23),
and the mean nursing practice years was 18.3 (9.76), range 6–38.
Data were missing for four APRNs on the fourth observation (after the 12th
participant was enrolled in each site). Therefore, APRN outcomes were analyzed
from pre-training to post-training after the sixth participant was enrolled at each site
(approximately 3 months post-training). APRN scores (N=11) on the Rx-OTC
knowledge and Rx-OTC self-efficacy scales increased from baseline to after the
APRN enrolled the sixth participant. Rx-OTC Knowledge increased from 67.7%
(11%) pre-training to 80.9% (12%) post-training (two tailed t=2.94, p=.014). Rx-
OTC Self-Efficacy increased from 3.82 (.61) pre-training to 4.13 (.47) 3 months
post-training (two tailed t=2.49, p=.016). The mean score on the 5-point Eldercare
Self-Efficacy Scale during pre-training (N=11) was 3.28 (.66), and it rose 3.67 (.67)
after the sixth participant enrolled (approximately 3 months later); the increase was
statistically significant (two tailed t=2.37, p=.039).
Baseline Characteristics of Patients
A total of 164 patient participants were screened for eligibility, 160 were eligible.
Two patients died during the course of the study (both in the control group). Ten
(6.25%) withdrew at various times during the study (five from the control group and
five from the intervention group). The baseline characteristics of participating
patients are shown in Table 1. There were no significant differences between the
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control and intervention groups for any of the demographic variables. Baseline
characteristics of the entire patient sample are described as follows. Patients had a
mean age of 68.59 (8.71) and were predominantly US born (89%), Caucasian (93%)
and females (78%). Twenty-three percent of them had monthly household incomes at
or below $1,500. Their mean REALM scores were at the high school level (grade
10–12) and 92% had at least a high school diploma or GED. BP Measurements
administered during the pre-intervention period on visit 1 revealed that 31% of all
participants were not at JNC-7 BP targets.
More than half of the participants (53.7%) had three or more chronic conditions. The
most common co-morbidities were high cholesterol (37.5%), arthritis (35.6%) anxiety
(21.8%) and diabetes (16.25%). The majority of participants (66.8%) rated their health
as very good or excellent during the preceding month. Most reported (63.2%) living
with someone else and 36.8% reported living by themselves. While a med box was
reported as the tool used most often (52.5%) to help them remember to take their
medications, 37.5% of the participants selected, “I just remember,” as their response.
The most common symptoms (during the last month reported by 20% or more of
participants) were pain, fatigue, difficulty sleeping, allergies, heartburn, cough, leg
cramps, anxiety and a cold. Medication labels and the pharmacist were reported as
the most common sources of medication information, followed by the doctor,
medication insert (dispensed by the pharmacy or the medicine package), and nurse.
Participants indicated that they buy OTC medicines primarily in grocery stores and
discount stores with pharmacists. Fewer than 5% of these participants reported
buying OTC medicines over the Internet.
A majority (73.6%) of participants took five or more Rx medications in the past
month, with a mean of 6.93 (3.41). When OTC agents were included, nearly all
(98.1%) of the participants reported taking five or more different medications in the
past month, with a mean of 11.41 (4.31). More than 12 medication doses per day
were taken by 9.5% of the participants. The most common medications reported are
profiled in Table 2. Self-reported medication adherence for antihypertensives was
high, with 89% or better daily adherence reported for each category of
antihypertensive. None of the participants reporting less than daily adherence on
all antihypertensives were at BP targets upon study entry.
Themean number of antihypertensive medication formulations prescribed to the study
participants upon entry to the study at visit 1 was 1.52 (0.83), with a range of 1–5. One
antihypertensive medication formulation was prescribed to 63.9% of the participants,
24.3% were prescribed two, 8.11% were prescribed three, 2.79% were prescribed four,
and 0.84% were prescribed five antihypertensive medication formulations.
A total of 44 different antihypertensive formulations were prescribed to the study
participants upon entry to the study at visit 1. The most common were: lisinopril (10%),
hydrochlorothiazide (8.1%), Toprol XL® (8.1%), atenolol (6.25%), Diovan® (4.4%),
and Coreg® (4.4%). The most common antihypertensive categories prescribed were
calcium channel blockers (41.9%), angiotensin converting enzyme inhibitors (ACEIs)
(38.8%), beta blockers (29.4%), angiotensin II receptor blockers (ARBs) (28.1%) and
thiazides (20.0%). Treatment with a single antihypertensive agent (monotherapy) was
prescribed to 65.3% of the patients upon entry to the study at visit 1.
Among participants not at BP targets upon study entry at visit 1, the mean number of
antihypertensive medication formulations was 1.45 (0.82), with a range of 1–4. One
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Table 1 Baseline characteristics of patient participants
Characteristic Total (N=160) Control (n=73) Intervention (n=87)
Age, mean (SD), years 68.6 (8.7) 69.6 (7.7) 67.8 (9.5)
Female sex (%) 125 (78.1) 60 (82.1) 65 (74.7)
Race, Ethnicity (%)
White or Caucasian 150 (93.7) 69 (94.5) 81 (93.1)
Black or African American 3 (1.8) 2 (2.7) 1 (1.1)
Asian 1 (0.6) 0 (0) 1 (1.1)
Native American 3 (1.8) 1 (1.3) 2 (2.3)
Hispanic or Latino 2 (1.2) 1 (1.3) 1 (1.1)
Hawaiian 1 (0.6) 0 (0) 1 (1.1)
Pacific Islander 0 (0) 0 (0) 0 (0)
More than one 0 (0) 0 (0) 0 (0)
Other 0 (0) 0 (0) 0 (0)
Born in US (%) 143 (89.3) 65 (89.0) 78 (89.7)
Monthly Household Income (%)
<$1,500 per month 20 (12.5) 11 (6.7) 9 (5.6)
About $1,500 per month 17 (10.6) 10 (6.3) 7 (4.3)
>$1,500 per month 117 (73.1) 50 (31.2) 67 (41.8)
No answer 6 (3.8) 2 (1.3) 4 (2.5)
REALM Score (SD) 65.3 (3.5) 65.4 (2.7) 65.1 (4.0)
Education, mean (SD), years 13.2 (2.8) 13.1 (2.3) 13.2 (3.1)
<12 y (%) 12 (7.5) 5 (6.8) 7 (8.0)
12 y or GED (%) 55 (34.3) 25 (34.2) 30 (34.4)
Some post-high school (%) 52 (32.5) 30 (41.1) 22 (25.2)
≥16 y (%) 41 (25.6) 13 (17.8) 28 (32.2)
BP, mean (SD), mm Hg
Systolic 128.3 (14.6) 127.4 (13.4) 129.1 (15.5)
Diastolic 74.5 (9.5) 74.27 (8.88) 74.7 (10.1)
At target on Visit 1 (%) 110 (68.7) 49 (67.1) 61 (70.1)
Not at target on Visit 1 (%) 50 (31.2) 24 (32.8) 26 (29.9)
Mean # chronic conditions (SD) 2.7 (1.7) 2.9 (1.6) 2.6 (1.7)
Co-morbidities
3 or more chronic conditions (%) 86 (53.7) 41 (56.1) 45 (51.7)
High blood pressure 139 (86.9) 66 (90.4) 73 (83.9)
High cholesterol 60 (37.5) 29 (39.7) 31 (35.6)
Arthritis 57 (35.6) 29 (39.7) 28 (32.1)
Anxiety 35 (21.8) 19 (26.0) 16 (18.3)
Diabetes 26 (16.3) 13 (17.8) 13 (14.9)
Irregular heartbeat 25 (15.6) 10 (13.7) 15 (17.2)
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Table 1 (continued)
Characteristic Total (N=160) Control (n=73) Intervention (n=87)
Osteoporosis 24 (15.0) 10 (13.7) 14 (16.1)
Depression 21 (13.1) 12 (16.4) 9 (10.3)
Asthma 17 (10.6) 9 (12.3) 8 (9.2)
Hypothyroidism 16 (10.0) 6 (8.2) 10 (11.5)
COPD 11 (6.9) 5 (6.9) 6 (6.9)
Cancer 4 (2.5) 2 (2.7) 2 (2.3)
Heart Attack 3 (1.9) 1 (1.4) 2 (2.3)
Stroke 1 (0.6) 0 (0) 1 (1.2)
Clot Legs 1 (0.6) 0 (0) 1 (1.2)
Ulcer 1 (0.6) 0 (0) 1 (1.2)
Medication Use
Rx Meds, mean (SD) 6.9 (3.4) 6.7 (3.5) 7.2 (3.4)
Range 1–20 1–17 2–20
OTC Agents, mean (SD) 4.7 (2.3) 4.8 (2.5) 4.5 (2.0)
Range 1–12 1–12 1–12
Total (Rx + OTC), mean (SD) 11.4 (4.3) 11.2 (4.7) 11.6 (4.0)
Range 3–29 3–29 5–25
5 or more Rx medications (%) 117 (73.6) 48 (65.8) 69 (80.2)
5 or more Rx + OTC medications (%) 156 (98.1) 70 (95.9) 86 (100)
12 or more doses/day (%) 15 (9.5) 6 (8.3) 9 (10.5)
Smoking Status (%)
Current Smoker 10 (6.2) 5 (6.8) 5 (5.7)
Using nictotine replacement 2 (1.2) 0 (0) 2 (1.2)
Alcohol Use (%) 90 (56.6) 37 (50.7) 53 (61.6)
≥3 drinks/day 2 (1.26) 0 (0) 2 (2.3)
Self-rated health in last month (%)
Poor 1 (0.6) 0 (0) 1 (1.1)
Fair 6 (3.7) 3 (4.1) 3 (3.4)
Good 42 (26.2) 22 (30.1) 20 (23.0)
Very Good 82 (51.2) 39 (53.4) 43 (49.4)
Excellent 25 (15.6) 8 (10.9) 17 (19.5)
Living Arrangements (%)
House 116 (72.5) 53 (72.6) 63 (72.4)
Mobile Home 3 (1.9) 2 (2.7) 1 (1.15)
Apartment 18 (11.2) 8 (10.9) 10 (11.4)
Condo 20 (12.5) 9 (12.3) 11 (12.6)
Senior Housing 3 (1.9) 2 (2.7) 1 (1.2)
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Table 1 (continued)
Characteristic Total (N=160) Control (n=73) Intervention (n=87)
Assisted Living 0 (0) 0 (0) 0 (0)
Other 1 (0.6) 0 (0) 1 (1.2)
Who Living With (%)
Live by self 59 (36.8) 26 (35.6) 33 (37.9)
Spouse 73 (45.6) 33 (45.2) 40 (45.9)
Child 14 (8.8) 4 (5.5) 10 (11.5)
Other Relative 11 (6.9) 5 (6.8) 6 (6.9)
Friend 4 (2.5) 3 (4.1) 1 (1.2)
Other adult 6 (3.8) 4 (5.5) 2 (2.3)
Other 1 (0.6) 0 (0) 1 (1.2)
Tools to Help Remember Meds (%)
Med Box 84 (52.5) 42 (57.5) 42 (48.3)
Just remember 60 (37.5) 26 (35.6) 34 (39.1)
Chart 7 (4.4) 4 (2.5) 3 (1.9)
Calendar 4 (2.5) 3 (4.1) 1 (1.2)
Cup 6 (3.8) 3 (4.1) 3 (3.5)
Other 8 (5.0) 2 (2.7) 6 (6.9)
Symptoms in last month (%)
Pain 75 (46.9) 38 (52.1) 37 (42.5)
Fatigue 55 (34.4) 29 (39.7) 26 (29.9)
Difficulty Sleeping 45 (28.1) 20 (27.4) 25 (28.7)
Allergies 41 (25.6) 16 (21.9) 25 (28.7)
Heart burn 38 (23.8) 14 (19.2) 24 (27.6)
Cough 38 (23.8) 15 (20.6) 23 (26.4)
Leg Cramps 36 (22.5) 18 (24.7) 18 (20.7)
Anxiety 33 (20.6) 15 (20.6) 18 (20.7)
Cold 33 (20.6) 16 (21.9) 17 (19.5)
Swollen Ankles 30 (18.8) 17 (23.3) 13 (14.9)
Bruising 30 (18.8) 20 (27.4) 10 (11.5)
Weight Gain 28 (17.5) 12 (16.4) 16 (18.4)
Cold Hands 27 (16.9) 13 (17.8) 14 (16.1)
Constipation 23 (14.4) 12 (16.4) 11 (12.6)
Dizzy 20 (12.5) 8 (11.0) 12 (13.8)
Diarrhea 19 (11.9) 5 (6.9) 14 (16.1)
Depression 19 (11.9) 12 (16.4) 7 (8.1)
Irregular heart beat 17 (10.6) 5 (6.9) 12 (13.8)
Vision problem 15 (9.4) 10 (13.7) 5 (5.8)
Nicotine Craving 11 (6.9) 6 (8.2) 5 (5.8)
Skin change 11 (6.9) 4 (5.5) 7 (8.1)
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Table 1 (continued)
Characteristic Total (N=160) Control (n=73) Intervention (n=87)
Weight Loss 7 (4.4) 4 (5.5) 3 (3.5)
Taste or Smell Changes 7 (4.4) 0 (0) 7 (8.1)
Memory problems 7 (4.4) 2 (2.7) 5 (5.8)
Sources of Medication Information (%)
Information on Label 110 (68.8) 41 (56.2) 69 (79.3)
Pharmacist 107 (66.9) 44 (60.3) 63 (72.4)
Doctor 84 (52.5) 35 (48.0) 49 (56.3)
Insert 49 (30.6) 22 (30.1) 27 (31.0)
Nurse 32 (20.0) 14 (19.2) 18 (20.7)
Articles 28 (17.5) 13 (17.8) 15 (17.2)
Internet 23 (14.4) 8 (11.0) 15 (17.2)
Books 11 (6.9) 9 (12.3) 2 (2.3)
Print Ads 10 (6.3) 4 (5.5) 6 (6.9)
TV 6 (3.8) 1 (1.4) 5 (5.8)
Relative 7 (4.4) 2 (2.8) 5 (5.8)
1–800 number 6 (3.8) 4 (5.5) 2 (2.3)
Friend 5 (3.1) 0 (0) 5 (5.8)
Other 1 (0.6) 0 (0) 1 (1.2)
None 0 (0) 0 (0) 0 (0)
Who helps take med (%)
I do 152 (95.0) 71 (97.3) 81 (93.1)
Spouse 4 (2.5) 0 (0) 4 (4.6)
Child 0 (0) 0 (0) 0 (0)
Relative 1 (0.6) 1 (1.4) 0 (0)
Friend 0 (0) 0 (0) 0 (0)
Nurse 0 (0) 0 (0) 0 (0)
Other 0 (0) 0 (0) 0 (0)
Where buy OTC medicines
Varies 0 (0) 0 (0) 0 (0)
Internet 7 (4.4) 3 (4.1) 4 (4.6)
Out of Country 0 (0) 0 (0) 0 (0)
Store with a pharmacist 129 (80.6) 59 (80.8) 70 (80.5)
Store without a pharmacist 26 (16.3) 11 (15.1) 15 (17.2)
Other 11 (6.9) 4 (5.5) 7 (8.1)
Grocery store 76 (47.5) 36 (49.3) 40 (46.0)
Discount store 54 (33.8) 19 (26.0) 35 (40.2)
Health food store 20 (12.5) 8 (11.0) 12 (13.8)
Convenience store 6 (3.8) 3 (4.1) 3 (3.5)
Other 47 (29.4) 23 (31.5) 24 (27.6)
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antihypertensive formulation (containing one or more antihypertensive agents) was
prescribed to 71% of the patients, 18.4% were prescribed two formulations, 5.3% were
prescribed three formulations and 5.3%were prescribed four antihypertensivemedication
formulations. Treatment with a single antihypertensive agent (monotherapy) was
prescribed for 57.9% of patients not at BP targets upon entry to the study at visit 1. (Of
those participants who were at goal upon entry at visit 1, 72.5% were on monotherapy).
Table 2 Medications self-reported at visit 1
Medication category N (%) N (%) N (%)
All Control Intervention
NSAID 84 (53.4) 38 (52.8) 47 (54.0)
Acetaminophen 48 (30.2) 20 (27.8) 28 (32.1)
Low Dose ASA 66 (41.9) 24(31.5) 43 (50.0)
Clopidogrel (Plavix) 13 (8.2) 7 (9.6) 6 (7.0)
Decongestant 37 (23.3) 16 (23.2) 21 (24.1)
Calcium Channel Blocker 67 (42.1) 31 (43.0) 36 (41.4)
ACEI 62 (39.0) 33 (45.8) 29 (33.3)
ARB 45 (28.3) 19 (26.4) 26 (29.9)
Beta Blocker 47 (29.6) 22 (30.6) 25 (28.7)
Thiazide 32 (20.1) 19 (26.4) 13 (14.5)
Table 1 (continued)
Characteristic Total (N=160) Control (n=73) Intervention (n=87)
Media Use
Radio, days/week (SD) 3.8 (1.5) 3.9 (1.5) 3.7 (1.4)
TV, days/week (SD) 4.1 (1.3) 4.2 (1.4) 4.0 (1.3)
Newspaper, days/week (SD) 3.9 (1.3) 3.9 (1.4) 3.8 (1.3)
Magazine, days/week (SD) 3.9 (1.3) 4.2 (1.3) 3.6 (1.3)
PC user (%) 104 (65.4) 43 (58.9) 61 (70.1)
Days PC (SD) 6.6 (2.0) 6.6 (1.9) 6.6 (2.0)
HRs/day PC (SD) 3.4 (1.8) 3.3 (1.8) 3.5 (1.7)
Internet user (%) 98 (61.6) 37 (50.7) 48 (67.6)
Days Internet 5.8 (2.3) 6.1 (2.1) 5.7 (2.4)
Hrs/day Internet 2.4 (1.1) 2.2 (1.0) 2.6 (1.2)
Email (SD)a 4.9 (1.2) 5.0 (1.1) 4.8 (1.3)
Travel (SD)a 3.0 (1.6) 3.0 (1.6) 3.0 (1.5)
Order (SD)a 2.7 (1.6) 2.9 (1.7) 2.7 (1.6)
Questionnaire (SD)a 1.9 (1.1) 2.2 (1.2) 1.8 (1.0)
Health (SD)a 3.8 (1.2) 4.0 (1.1) 3.7 (1.2)
Video (SD)a 2.5 (1.2) 2.4 (1.2) 2.5 (1.3)
a 0-7 scale where 0 = never, 1 = very rarely, 7 = very often
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In terms of offline media exposure, participants from the control and
intervention groups appeared to consume radio, television, newspaper and
magazine content on a similar number of days per week (3.6 vs. 4.2). Even
though fewer participants from the control group were PC users than the
intervention group (58.9% vs. 70.11%), this discrepancy was not statistically
significant (Χ2 (1, 157)=2.52, p=.1118) and both groups used a personal computer
on 6.6 days per week (or nearly 7 days a week) and about 3.3–3.4 h per day. There
were significantly fewer Internet users in the control group compared to the
intervention group (50.7% vs. 67.6%) (Χ2 (1, 157)=6.89, p=.0086), but the number
of days per week (5.67 vs. 6.01) and hours per day (2.24 vs. 2.56) each group of Internet
users went online was not significantly different. The number of days these two Internet
user groups used the email system per week (4.82 vs. 4.97) was not statistically
Table 3 Mean knowledge, self-efficacy and risk scores and BP values (all patients)
Outcome Visit Control SD Intervention SD
Rx-OTC Knowledge 1 45.6 14.6 45.2 16.4
2 44.8 17.0 51.0a 16.5
3 46.4 16.5 57.0a 15.3
4 45.1 16.2 59.4a,b 16.4
Rx-OTC Self-efficacy 1 2.3 0.9 2.5 0.9
2 2.4 0.8 2.7a 0.9
3 2.6 0.8 3.0a 0.8
4 2.5 0.8 3.3a,b 0.7
Adverse Behavior Risk Score 1 16.6 15.9 17.9 15.4
2 12.6 12.6 16.4 13.4
3 14.1 13.3 15.9 12.9
4 14.2 13.5 13.4c 11.2
SPB mm Hg 1 127.4 13.4 129.1 15.5
2 128.8 13.3 128.6 15.2
3 128.6 15.9 125.8 13.2
4 128.5 13.6 126.5 13.5
DBP mm Hg 1 74.3 8.8 74.7 10.1
2 73.8 7.1 74.6 10.5
3 73.0 8.0 73.0 9.8
4 74.3 8.8 72.7 8.9
a Post hoc two sample t tests detected significant differences (p<.05) between intervention and control
groups at visits 2, 3, 4
b Post hoc paired t tests detected significant increases (p<.05) within intervention group between visit 1
and visits 2, 3 and 4
c Post hoc paired t tests detected a significant decrease (p<.05) in transformed behavior risk score between
visit 1 and visit 4
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differentiated, nor was their access to different types of online content (e.g., travel and
health). Lastly, the Internet self-efficacy level was not significantly different between the
control-group Internet users (mean (SD)=2.03 (0.76)) and the intervention-group
Internet users (mean (SD)=2.15 (0.75)) upon entry to the study. Moreover, Internet self-
efficacy for both groups did not change across visits 1–4.
Patient Outcomes: All Patients
Table 3 shows the results for Rx-OTC knowledge, Rx-OTC self-efficacy, and
adverse self-medication behavior risk scores, as well as BP for all patients in the
study. Both control and intervention patients took approximately 43 min to answer
all of the questions on visit 1 (control patients: mean (SD)=42.75 (15.6) minutes;
intervention patients: mean (SD)=42.83 (15.3) minutes). Time spent on the PEP-NG
for the following visits (wherein the demographic and media use questions were
omitted) took approximately 25 min on visit 2 (control patients: mean (SD)=25.6
(9.0) minutes; intervention patients: mean (SD)=25.5 (11.4) minutes) and 24 min on
visit 3 (control patients: mean (SD)=23.9 (8.4) minutes; intervention patients: mean
(SD)=24.4 (11.0) minutes). Visit 4 repeated the media-use questions and contained
the satisfaction scale. Mean (SD) time spent on visit 4 was 28.2 (8.9) minutes for
control patients and 34.9 (13.3) minutes for intervention patients.
Adverse Self-Medication Behavior-Risk Score
Normality of the behavior-risk score was tested with the Shapiro and Wilk’s W
statistic. The skewness value was 1.4 and the kurtosis value was 2.99. The W
statistic was 0.877, and normality was rejected at the 0.05 level of significance. The
SAS boxcox method determined that the square-root function (square-root risk) was
the best transformation of the behavior-risk score, producing a skewness value of
0.25, a kurtosis value of −0.66, and a W statistic of 0.96. Consequently, the square-
root risk (transformed behavior-risk score) was used in all analyses.
While there was no significant condition by visit interaction for the transformed
behavior-risk score, main effects were significant for visit (F (3, 418, p<.0180).
There was a significant linear trend (F (1, 418)=5.18, p=.0233), but there was no
significant quadratic or cubic trend. Results of post hoc paired t-tests and
nonparametric tests showed a significant reduction in the transformed behavior-
risk score for the intervention group from visit 1 to visit 4 (paired t (73)=2.17,
p=.033; Cochran-Mantel-Haenszel statistic (1, 161)=4.44, p=0.035).
Rx-OTC Knowledge
Knowledge scores were normally distributed. The interaction between visit and
condition was significant (F (3, 411)=7.15, p=.0001). Main effects were significant
for computer use (F (1, 139)=5.67, p=.0186), gender (F (1, 139)=24.1, p<.0001),
condition (F (1, 139)=20.51, p<.0001), and visit (F (3, 411)=10.07, p<.0001).
There was a significant linear trend for visit alone (F (1, 411)=26.76, p<.0001) and
for visit within the intervention group (F (1, 411)=36.51, p<.0001). Post hoc
analyses detected significant differences between the control and intervention group
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at visits 2, 3 and 4, with a large effect size on visit 4 (Cohen’s d=0.877). Within the
intervention group, there was a significant difference between visit 1 and 2, 2 and 3,
and 3 and 4. There was also a significant increase in knowledge from visit 1 to visit
4 for the intervention group (paired t (73)=6.26, p<0.0001). Post hoc paired t-tests
showed no significant change in knowledge from visit 1 to visit 4 for the control
group. The main effect of being a computer user resulted in a larger knowledge score
overall of 5.2 in the percent correct. By contrast, the main effect of gender resulted in
males having a lower knowledge score overall of |- 9.97| in the percent correct. Rx-
OTC knowledge scores were significantly correlated with Transformed Behavior
risk score for the control group on visit 4 (Spearman r (141)=.41, p=.0007).
Rx-OTC Self-Efficacy
Self-efficacy scores were normally distributed. The interaction between visit and
condition was significant (F (3, 412)=9.33, p<.0001). Main effects were significant
for condition (F (1, 139)=9.67, p=.0023) and visit (F (3, 412)=23.68, p<.0001).
There was a significant linear trend for visit alone (F (1, 412)=70.52, p<.0001), in
addition to visit within the both the control group (F (1, 412)=5.15, p=.0237) and the
intervention group (F (1, 412)=61.70, p<.0001). Post hoc analyses detected
significant differences between the control and intervention group at visits 2, 3 and
4, with a large effect size on visit 4 (Cohen’s d=1.06). There were significant
differences between visits 1 and 2, 2 and 3, as well as 3 and 4 in the intervention
group. Post hoc paired t-tests showed a significant increase in self-efficacy from visit 1
to visit 4 for the intervention group (t (73)=10.38, p<0.0001). There was no
significant change in self-efficacy from visit 1 to visit 4 for the control group.
With the exception of Rx-OTC knowledge scores and Transformed Behavior Risk
scores on visit 4 in the control group as described above, correlations were weak
among Transformed Behavior Risk, Rx-OTC knowledge scores, Rx-OTC self-
efficacy scores, and education. These variables were not correlated with SBP or DBP
at any visit for either controls or intervention patients.
Blood Pressure
Both SBP and DBP values were normally distributed. There was no significant
interaction between visit and condition for either SBP or DBP.Main effects on SBPwere
significant for age (F (1, 139)=4.22, p=.0419), income (F (1, 139)=6.41, p=.0125),
and condition (F (1, 139)=5.50, p=.0204). There was no linear, quadratic or cubic
trend. The main effect of age resulted in a larger SBP overall of 0.25 mm Hg per year
(i.e. an increase of 10 years in age added 2.5 mm Hg overall to SBP). The main effect
of higher income (above $1,500 per month) was a lower SBP overall of -2.68 mm Hg.
The main effect of being in the control condition was a higher SBP overall of 3.6 mm
Hg. Post hoc paired t-tests did not reveal any significant differences in the SBP of visit
1 with visits 2, 3 or 4 within either group.
Main effects on DBPwere significant for computer use (F (1, 139)=4.73, p=0.0314)
and condition (F (1, 139)=5.69, p=.0184). There was no linear, quadratic or cubic
trend. The main effect of being a computer user resulted in a higher DBP overall of
2.37 mmHg. Moreover, the main effect of being in the control condition was a larger
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DBP overall of 2.18 mmHg. Post hoc paired t-tests did not reveal any significant
differences in the DBP of visit 1 with visits 2, 3 or 4 within either group.
The percentage of control group participants not at their BP target went from
32.9% on visit 1 to 31.3% by visit 3. This represents a 4.8% reduction in the
percentage of control group participants not at BP targets at visit 3 compared to visit
1. The percentage of control group participants not at BP targets was at 35.3% by
visit 4 (an increase of 7% compared to visit 1). The percentage of intervention
participants not at their BP target went from 29.9% on visit 1 to 21.8% by visit 3.
This represents a 27% reduction in the percentage of intervention participants not at
goal at visit 3 compared to visit 1. The percentage of intervention participants not at
goal was at 26% on visit 4 (a reduction of 13% compared to visit 1).
Satisfaction With PEP-NG
Satisfaction scores are shown in Table 4. Participants in both groups indicated a high
level of satisfaction with aspects of the PEP-NG interface and program. Compared to
Table 4 Degree of satisfaction and intent to change
Control Intervention
(n=64) (n=71)
Mean (SD)a Mean (SD)a
Satisfaction Statement
The movies were useful. 4.0 (0.6) 4.1 (0.7)
The questions were useful. 4.1 (0.6) 4.2 (0.5)
The program was easy to use. 4.4 (0.6) 4.4 (0.6)
The program was fun to use 4.1 (0.7) 4.2 (0.7)
The program was easier to understand than medicine labels. 3.9 (0.8) 4.2 (0.7)
Much of the information in the program was new for me. 3.6 (0.8) 4.1(0.7)*
I will recommend this program to my friends. 4.1 (0.7) 4.2 (0.6)
I would choose to other programs like this one in the future. 4.2 (0.6) 4.1 (0.7)
The advice in the program suited my special needs. 3.8 (0.8) 4.2 (0.6)*
Overall mean satisfaction score 4.0 (0.4) 4.2 (0.5)*
Intent to Change Statement:
This program helped me want to change how I use medicines. 3.6 (0.9) 4.2 (0.7)*
After using this program I will make some changes in how I use medicines. 3.4 (1.0) 4.0 (0.9)*
After using this program I will change when I take some medicines. 3.4 (1.0) 4.0 (0.9)*
This program helped me think of questions to ask my doctor. 4.0 (0.7) 3.9 (0.8)
This program helped me think of questions to ask my pharmacist. 3.8 (0.7) 3.8 (0.8)
This program helped me think of questions to ask my APRN 4.1 (0.7) 3.9 (0.8)
Overall mean intent to change score 3.7 (0.7) 4.0 (0.6)*
a Mean degree of agreement with statement; 1 = strongly disagree to 5 = strongly agree
*Two sample t test significant difference (p<.05) between groups
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the control group, the intervention group had significantly higher overall mean
satisfaction scores (t (132)=2.04, p=.0431). Post hoc t-tests revealed significantly
higher ratings in the intervention group on two satisfaction items: “Much of the
information in the program was new for me,” (t (132)=3.83, p=.0002) and “The
advice in the program suited my special needs,” (t (132)=3.14, p=.0016).
The intervention group had a significantly higher “mean intent-to- change” score
compared to the control group (t (132)=2.16, p=.033). Post hoc t-tests revealed a
significantly greater score for the intervention group on three intent-to-change items:
“This program helped me to want to change how I use medicines,” (t (132)=4.04,
p=.0001), “After using this program I will make some changes in how I use
medicines,” (t (132)=3.424, p=.0008), and “After using this program I will change
when I take some medicines,” (t (132)=3.60, p=.0005).
Satisfaction With the APRN Provider Relationship
Scores (SD) on the 5-point Likert type Healthcare Relationships Scale were
similar for the control group (4.46 (0.83), n=69) and the intervention group (4.40
(0.68) n=82) participants upon entry to the study on visit 1. On visit 4, scores (SD)
remained high with means of 4.42 (0.63) for the control group (n=65) and 4.34
(0.60) for the intervention group (n=75).
Patient Outcomes: Patients not at BP Targets Upon Entry to the Study
Sub analyses conducted for the study participants in both groups not at BP targets
upon entry to the study are given in Table 5.
Table 5 Mean risk scores and BP values (patients not at BP targets upon entry to study on visit 1)
Outcome Measure Visit N Control SD N Intervention SD
Adverse Behavior Risk 1 24 20.8 19.5 26 23.3 19.8
2 23 15.4 13.0 23 16.1 12.0
3 21 15.1 11.1 22 13.9 10.4
4 21 18.5 15.1 22 11.7* 8.2
SBP mm Hg 1 24 139.9 10.7 26 146.2 9.8
2 23 133.7* 15.8 25 139.0* 16.4
3 21 130.5 21.4 23 129.0* 13.9
4 21 133.8* 13.3 22 130.6* 11.5
DBP mm Hg 1 24 77.5 8.3 26 81.1 11.6
2 23 73.6 7.0 25 79.5 13.1
3 21 71.1* 6.7 23 76.7 11.4
4 21 75.2 8.8 22 74.8* 9.2
* Post hoc paired t tests detected significant decrease (p<.05) compared to visit 1
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Adverse Self-Medication Behavior Risk Score
There was a significant visit effect for transformed behavior risk score for those
participants not at BP targets upon entry to the study (F (3, 125)=2.75,
p=.0454). There was no interaction with condition or gender. While there was a
significant linear trend (F (1, 125)=4.31, p=.040), there was no quadratic or cubic
trend. There was a 49.8% reduction in the Behavior Risk Score on visit 4 for the
intervention patients who were not at BP targets upon entry to the study. Results of
post hoc paired t-tests and nonparametric tests showed a significant reduction in
transformed behavior risk score for the intervention group from visit 1 to visit 4
(paired t (21)=2.41, p=.0253; Cochran-Mantel-Haenszel statistic (1, 48)=5.76,
p=.0164).
Blood Pressure
There was no significant interaction between visit and condition for SBP among
participants not at BP targets on study entry. Main effects on SBP were significant
for income (F (1, 34)=4.44, p=.0425) and visit (F (3, 129)=9.54, p<.0001). There
was a significant linear trend for visit alone (F (1, 129)=20.26, p=<.0001), and a
significant quadratic trend for visit alone F (1, 129)=7.14, p=<.0085). There was
also a significant linear trend for visit within both the control (F (1, 126)=6.27,
p=.0136) and intervention (F (1, 126)=21.53, p=<.0001) groups. The main effect
of higher income (above $1,500 per month) was a lower SBP overall of |−5.2|
mmHg (both groups considered together). Post hoc paired t-tests showed
significant reductions in SBP from visit 1 to visit 4 in both the control
(−6.11 mm Hg) (t (20)=2.22, p=.0380) and the intervention (−15.51 mm Hg)
(t (21)=5.95, p<.0001) groups. The intervention group had a medium effect size
in reducing SBP (Cohen’s d=.2548) among patients not at BP targets upon entry
to the study. Post hoc paired t-tests also showed significant declines for SBP in the
intervention group from visit 1 to visit 2 and 3.
Main effects on DBPwere significant for visit (F (3, 129)=3.48, p=.0178). There was
a significant linear trend for visit alone (F (1, 129)=8.04, p=.0053). There was also a
significant linear trend for visit within both the control (F (1, 126)=4.68, p=.0324) and
intervention (F (1, 126)=3.92, p=.0498) groups. The decline in DBP (−2.31 mm Hg) in
the control group from visit 1 to visit 4 was not statistically significant. By contrast, the
intervention group had a 2.70 fold greater decline in DBP (−6.26 mm Hg) from
visit 1 to visit 4 compared to the control group, which was statistically
significant (paired t (21)=3.70, p=.0013).
Among all patients (both groups) at BP targets upon entry to the study who
reported being Internet users, Internet Self-efficacy was significantly correlated
with Rx-OTC self-efficacy on visit 4 (Spearman r (50)=.4417, p=.0015). Among
the control group participants not at BP targets upon entry to the study,
Transformed Behavior Risk score was significantly correlated with SBP on visit
2 (Spearman r (21)=.51298, p=.0207) and Rx-OTC Knowledge scores on visit 4
(Spearman r (22)=.64312, p=.0017).
In patients who were not at BP targets at study entry, movement to controlled BP
was uneven, but not significantly different, between the intervention and control
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groups. Among 22 patients not at BP targets in the intervention group at visit 1, 14
(63.6%) had controlled BP at visit 4. In contrast, among 21 patients initially not
at BP targets in the control group, only 8 (38.1%) had controlled BP at visit 4.
The odds ratio comparing frequencies of these changes between groups was 2.84
(Χ2 (1)=2.81, p=0.094, 95% CI: [0.83, 9.80]).
Changes in Patient Behaviors Affecting BP
Adherence was considered to be the percentage of patients reporting taking all of
their antihypertensive medications “daily.” Of patients not at BP targets on visit 1
(both control and intervention groups), 93% self-reported taking all of their
antihypertensives daily upon entry to the study. Self-reported daily adherence rose
to 100% of patients in both groups of patients on visit 2 and remained at 100% of
patients on the ensuing 2 visits for the intervention group, while 95% of control
patients reported daily adherence on visits 3 and 4. Among control patients who
were at BP targets upon entry to the study, self-reported adherence declined over
time to 87% by visit 4. Self-reported daily adherence stayed close to 95% or greater
during the subsequent three visits for intervention patients who were at BP targets on
study entry.
More than half of patients not at BP targets upon entry to the study reported
NSAID usage in the previous month (54.2% of control and 57.7% of intervention
patients). Patients in the intervention group reduced self-reported NSAID use over
time from 57.7% upon study entry to 9.09% on visit 4, while 42.8% of the control
group still reported NSAID usage at visit 4. Monthly NSAID use was categorized
as: 1) 1–10 days/month; 2) 11–20 days/month; 3) 21–31 days/month; and 4) other.
Results of a Cochran-Armitage test for trend detected a significant declining linear
trend in proportion of the intervention patients in category 3 (taking NSAIDs 21–
31 days/month) (Z (35)=2.5023; Exact test one sided p=.0084).
Alcohol has a pressor effect in a dose-related manner beginning at >2 drinks/day
(World Hypertension League 1991). Among patients not at BP targets upon entry to
the study, 41.4% of controls and 57.7% of intervention patients reported daily
alcohol consumption. None of the control-group patients and two of the
intervention-group patients reported having three or more drinks daily in the month
prior to study entry. Both of these intervention-group patients reduced their self-
reported daily alcohol consumption to one drink/day. (One reduced to one drink per
day by visit 2, the other reduced to one drink by visit 3. Both of them reported one
drink per day on visit 4).
Decongestants can increase BP to a variable degree—depending on agent, dose,
and duration of use (Johnson and Hricik 1993; Kollar et al. 2007; Salerno et al.
2005)—but effects in older adults have not been well studied. Five (20.8%) of the
control group patients and 6 (23.1%) of the intervention group patients not at BP
targets upon study entry reported taking a medication containing a decongestant on
visit 1. Of these patients, (40%) in the control group and three (50%) in the
intervention group reported taking the decongestant medication daily. On visit 4, 6
(28.6%) in the control group and 3 (13.6%) in the intervention group reported taking
a medication containing a decongestant in the previous month. The ability of the
PEP-NG to capture decongestant taking behaviors was limited for the following
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reasons: 1) decongestant taking behaviors may be episodic in nature due to seasonal
allergies and colds; 2) OTC cold medications underwent reformulation during the
trial period to replace pseudoephedrine with phenylephrine; and 3) study entry was
on a rolling basis. Therefore, data on decongestant taking behaviors were not
analyzed for time trends.
Provider Changes to Antihypertensive Regimen
Table 6 shows changes made in patient antihypertensive regimens during the study
period for patients not at BP targets on visit 1. For controls, 11 (45.8%) patients not at
BP targets on visit 1 had either an increase in dose or an added antihypertensive Rx.
Only one intervention patient (3.85%) had an added antihypertensive Rx and none had
a dose increase. For controls, 2 (8.33%) of patients had either a decrease in dose or an
antihypertensive Rx discontinued. For intervention patients, 5 (19.32%) had either a
decrease in dose or an antihypertensive Rx discontinued. A Fisher’s exact test on
therapy intensification (the number of patients receiving an increased antihyper-
tensive dose and/or an additional antihypertensive) was significant (p=.001) with
an odds ratio of 21.27, 95% CI: [2.45, 200] for the control group compared to the
intervention group.
NSAID Use Among Patients Taking Daily Low-Dose Aspirin
Providers may recommend low-dose aspirin for patients with hypertension because
of its antiplatelet effects and its contribution to lowering BP in the morning hours, if
taken in the evening prior (Hermida et al. 2005). Resistance to the antiplatelet effects
of low-dose aspirin may be due to low adherence rates to low-dose aspirin therapy,
genetic polymorphisms, or high platelet counts (Tran et al. 2007). Another potential
cause of aspirin resistance is frequent concurrent use (3 days or more per week) of
NSAIDs (Gladding et al. 2008; MacDonald and Wei 2003; Tran et al. 2007). As
shown in Table 2, 31.5% of control-group patients and 50% of intervention-group
Table 6 Changes in antihypertensive regimen made by provider (Of patients not at BP targets upon entry
to study on visit 1)
Control (n=24) Intervention (n=26)
Change (%) Change (%)
No Change 15 (62.5) 16 (61.5)
Increased Dose 4 (16.7%) 0 (0)
Added Rx 7 (29.2) 1 (3.9)
Switched Rx 3 (12.5) 3 (11.5)
Decreased dose 2 (8.3)a 3 (11.5)b
Discontinued Rx 0 (0) 2 (7.7)
a 2 patients, each with 1 prescription
b 3 patients, 5 prescriptions total
Note: In cases where an Rx was “switched” – the Rx were not also considered as “added Rx” or
“discontinued Rx”
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patients reported taking daily low-dose aspirin at visit 1 upon entry to the study. Of
patients taking daily low-dose aspirin, 44.7% of control and 45.4% of intervention
group patients reported taking NSAIDs on a frequent basis of 3 days a week or more
(26.3% of all control and 36.4% of all intervention patients who reported taking
daily low-dose aspirin also reported taking an NSAID daily).
Among patients not at BP targets upon entry to the study, 71% of controls and
65% of intervention group patients reported taking daily low-dose aspirin at visit 1
upon entry to the study. Of these, 58.8% of control and 64.7% of intervention group
patients also reported taking NSAIDs on a frequent basis of 3 days a week or more;
29.4% of these controls and 52.9% of these intervention patients reported taking an
NSAID daily. By visit 4, 69.2% of the controls and none of the intervention
participants who indicated taking daily low-dose aspirin reported frequent NSAID
use of 3 days a week or more (30.8% of control patients who reported taking daily
low-dose aspirin still reported taking an NSAID daily on visit 4). Categorizing
monthly NSAID use as described above and applying the Cochran-Armitage
test for trend detected a significant declining linear trend across the four visits,
in proportions of intervention participants who took NSAIDs 21–31 days/month
(Z (29)=2.6049, Exact test one sided p=.0062). There were no significant trends in
NSAID use among patients in either group who were at BP targets upon entry to
the study, regardless of low-dose aspirin use.
Antihypertensive/NSAID Combinations That Can Impair Renal Function
Taking NSAIDs with the combination of diuretics and either ACEIs or ARBs
increases the risk of renal impairment in older adults (Juhlin et al. 2005; Loboz and
Shenfield 2004). Among all participants in the study, 15.7% took either an ACEI or
ARB and took a diuretic and NSAIDs concurrently in the previous month on visit 1.
By visit 4, this combination was taken by 23.5% of control-group patients, compared
to 12% of intervention-group patients. Among patients not at BP targets upon entry
in to the study, 33.3% of the control group and none of the intervention-group
participants were taking this nephrotoxic combination on visit 4. Among the control-
group participants not at BP targets on visit 1– in five of seven cases where a Rx was
added to the antihypertensive regimen—the Rx added was a diuretic; in four of these
cases, the patient also reported taking an NSAID (other than low-dose aspirin) in the
previous month. In two of the four cases where an antihypertensive dose was
increased to control BP, the agents were diuretic/ACEI combinations and both of these
participant also reported taking NSAIDs in the previous month.
Discussion and Conclusions
Discussion
Older adults’ risk of potential adverse drug interactions (PADI) is greatly increased
when they have three or more chronic illnesses, take five or more concurrent
medications, ingest more than 12 medication doses taken per day, have a history of
nonadherence, or take a drug that requires therapeutic monitoring (Isaksen et al. 1999).
In the current study, 53.7% of the participants had three or more chronic illnesses, 98%
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reported taking five or more different medications in the past month (combining both
Rx and OTC medications), and 9.5% took 12 or more medication doses per day. This
suggests that nearly all of the participants were at risk for a PADI. That 37% of patient
participants selected “just remember” as the only means that helps prompt them to take
their medications is disconcerting and supports past findings that older adults make
infrequent use of medication management tools (Lakey et al. 2009).
Satisfactionwith the PEP-NG interface and theAPRN provider relationship were high
in both the intervention and control groups. The intervention group had significantly
higher scores on the “intent to change” subscale. Both groups in the current study had
high mean scores on the “health care provider relationship” scale, indicating a high
degree of trust in and satisfactionwith their care, as well as feeling involved in their health
care decisions and an ease and comfort in communicating with their APRN provider.
Compared to the control condition, participants in the intervention group
demonstrated significant increases in both Rx-OTC self-medication knowledge and
self-efficacy measures (with large effect sizes) via repeated measures. Moreover,
patients in the intervention group did not need more interface time to complete the
longer education/learning-outcome assessment content than those in the control
group to achieve increased knowledge and self-efficacy. These results could be
indicative of the user-friendly nature of the tailored PEP-NG system—which enables
the users to tailor their own learning style and focus to maximize their learning
outcomes—such as concentrating on remedying their riskiest self-medication
behaviors (as revealed by the PEP-NG’s built-in risk-score calculation metrics).
These findings provide a strong testament to the advantage of an e-health intervention
with tailored content and an interface design which was iteratively tested and
validated for system usability and content usefulness (see Lin et al. 2009, 2010).
The study evidence shows that SBP and DBP declined in both intervention and
control-group patients who were not at BP targets upon study entry. However, the
decrease in the intervention group was more than two-fold greater than that in the
control group having both clinical and statistical significance. A report prepared for
the Agency for Healthcare Research and Quality (AHRQ) documented the mean
reductions in SBP and DBP as 4.5 mm Hg and 2.1 mm Hg respectively, across all
studies examined and a variety of BP management strategies (Shojania et al. 2005).
The present study found mean BP reductions of 15 mm Hg for SBP and 6 mm Hg
for DBP among the intervention-group participants. According to unbiased estimates
of efficacy from a recent meta-analysis of BP reduction and cardiovascular outcomes
(Law et al. 2009), a reduction of 10 mm Hg in systolic BP or 5 mm Hg in diastolic
BP reduces coronary heart disease events by 22% and stroke by 41%.
The manner in which patients moved to BP targets in the current study differed
between the intervention and control groups. Providers intensified antihypertensive
therapy by adding new antihypertensives and/or increased doses with an OR of
21.27 in the control group, compared to the intervention group. The intervention
group changed behaviors that counteracted the efficacy of antihypertensives—by
significantly decreasing NSAID use and intake frequency—and, in two cases,
decreasing alcohol consumption. Self-reported adherence (taking all antihyperten-
sives daily) reached 100% in the intervention-group participants who were not at BP
targets upon entry to the study. Of particular concern is that therapy intensification in
the control patients not at BP targets upon study entry resulted in placing 33 t% of
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those patients at added renal risk because of continuing, concurrent NSAID use. The
American Geriatrics Society guidelines specifically note that this so called “triple
whammy” (Loboz and Shenfield 2004) combination (ACEIs/ARBS, thiazides, and
NSAIDS) should be strictly avoided (American Geriatrics Society 2009).
Upon entry to the study, 53.4% of participants reported taking NSAIDs in the
previous month, a practice that should be avoided in older patients with hypertension,
because NSAIDs both increase BP as well as counteract the efficacy of antihypertensives
and low-dose aspirin (American Geriatrics Society 2009). The current study findings
were somewhat dissimilar to the results reported by a recent cross-sectional home-
interview study. This particular study, a nationally representative probability sample of
3,500 older adults, examined the use of Rx and OTC agents by ranking specific medica-
tion ingredients (rather than categories of agents); none of the NSAIDs were mentioned
among the top 20 most commonly used medications by study participants (Qato et al.
2008). Qato et al. (2008) also found lower rates of low-dose aspirin use among their
study participants (28%), compared to the participants in the current study (41.9%).
Among intervention participants not at BP targets upon entry to the study, NSAID
use was greatly reduced by visits 2–4, both in terms of numbers of patients reporting
any NSAID use and frequency of use. This likely had a major influence on the
greater reductions in both SBP and DBP in the intervention group. The findings that
NSAID usage significantly declined only among intervention patients not at BP
targets upon study entry, but not among control group patients or patients in either
group who were at BP targets upon study entry, is an important one, suggesting that
patients whose BP was under control were less likely to heed advice to avoid self-
medication with NSAIDs.
It is also of interest that none of the participants who reported less than daily
adherence for all of their antihypertensives were at BP targets upon study entry.
Patients who self-report nonadherence, as identified by their answer to the
question—“In the last month, how often did you take your medications as your
doctor prescribed?”—have as great a cardiovascular risk as patients who smoke
or have diabetes (Gehi et al. 2007). While the PEP-NG may over estimate
adherence and cannot provide precise adherence data, nonadherence documented
on the PEP-NG printout can foster patient-provider communication about reasons
the patient did not adhere to the prescribed therapy.
Limitations
The study design consisted of four monthly APRN provider visits. This intervention
design may be considered a study limitation, as clinical interventions involving repeated
visits have resource and workflow barriers to widespread implementation in a clinical
setting. Another potential limitation associated with this study is that the BP measure-
ments were taken by the participating APRN and could be subject to observer bias. As
patients self-referred to the study, the percentage of patients not at BP targets at study
entry (31.2%) may not have been representative of the patient population at the practice
sites and was not representative of the U.S. as a whole (Chobanian et al. 2003). In
general, participants were predominantly female, Caucasians; they also had higher
health literacy (REALM) scores, education attainment, and self-health ratings than the
population of adults aged 60 and older with hypertension (Bennet et al. 2009).
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Therefore, participants may not reflect the general population of patients in the primary
care practices with respect to either demographic characteristics or degree of adherence
to their antihypertensive regimen. While the characteristics of the participants limit
generalizability of study results, the findings do support the feasibility of a content-
tailored e-health intervention with older adults in primary care practices.
Despite fairly homogeneous participant characteristics, participants did have
income diversity with 23% reporting a monthly income at or below $1,500. The
results suggest that income did not play a role in Rx-OTC knowledge and self-
efficacy scores, adverse self-medication risk scores, or BP. Gender was found to
have a main effect in Rx-OTC knowledge scores (with approximately a 10% lower
knowledge score overall for males); this suggests that older men in the study were
less likely to obtain information on OTC agents and their interactions with
antihypertensives. Computer users had an overall 5% higher Rx-OTC knowledge
scores; this indicates that prior computer-use experience may provide a small
advantage in learning from computer-based education programs or seeking
knowledge about medications and OTC agents from computer-based sources.
The finding that Rx-OTC knowledge was significantly correlated with trans-
formed adverse self-medication risk scores for the control group on visit 4 suggests
that knowledge alone does not necessarily transfer to safe medication-taking
behaviors. This is because patient self-efficacy is a key motivating factor for
behavioral adoption and change, as evidenced by the large effect size found in both
knowledge and self-efficacy for the intervention group. These findings confirm
Bandura’s theory that knowledge and self-efficacy are separate domains and both are
essential to effecting positive behavior change (Bandura 1997). Naturally, the role of
patients’ computer and Internet efficacy should also be considered when implementing
an e-health intervention program. As suggested by past literature, while a large
percentage of older adults have basic computer and Internet-use skills, they are also
intrigued by and enthusiastic about becoming more computer and Internet literate
(Alemagno et al. 2004; Lin et al. 2009; Nahm et al. 2004).
Conclusions
With the median time of a primary care visit at 14 min (Hing et al. 2006), providers
lack the time to elicit patient medication-taking behaviors or conduct a comprehen-
sive review of medications taken on a regular basis (Tarn et al. 2009). The provider
support offered by the PEP-NG printouts (symptoms, Rx, and OTC agents taken,
including frequency and timing) can free up time for the provider to engage in the
sorely needed provider-patient communication by reinforcing the patient-tailored
education outcomes derived from the PEP-NG interface. PEP-NG use implanted
during patients’ “waiting-room time” can identify their symptoms and those with
PADIs, in addition to allowing them to initiate an e-health education experience that
is tailored to their specific self-medication behaviors.
As demonstrated by the current study, an on-site e-health intervention combined
with provider-patient follow-up communication has produced significant and
positive health outcomes for study participants. As patients took only 25 min to
interface with the PEP-NG on the two follow-up visits, which omitted demographic,
media use, and satisfaction questions, a repeated e-health intervention procedure is
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both feasible and doable in a clinical setting. As the current PEP-NG intervention
was able to generate large effect sizes on knowledge and self-efficacy, by omitting
the knowledge and self-efficacy scales in follow-up visits, the concern about time
efficiency should also be mitigated.
The study described herein is an efficacy trial in the “realistic setting” of primary
care practice. Additional studies of provider workflow using the PEP-NG and health
care utilization costs are under way. A cost-benefit analysis (CBA) using data from
time-motion studies and 52-week health care utilization data (i.e. total number of
provider visits, emergency room visits, and hospitalizations) following each
participant’s entry to the study is being conducted and will be reported separately.
Future study with the PEP-NG will involve implementation on a wider scale with
both provider-site and in-home access to the PEP-NG portal. Patients who are
Internet users will be allowed to complete the program at home with reports
generated to their provider prior to their office visits. This could greatly reduce the
numbers of patients who would need to use the PEP-NG on-site at the provider’s
office and permit wider implementation in a given primary care practice. The target
audience of the PEP-NG will also be expanded to patients diagnosed with pre-
hypertension (BP greater than 120/80 but lower than BP targets).
The patient gains found in the current clinical trial resulting from the e-health
intervention suggest that the PEP-NG system can be instrumental in facilitating
better patient care in the primary care setting. A cost-effective and time-efficient e-
health intervention system such as the PEP-NG can become a model for guiding
other self-management and medication-adherence interventions directed at other
major national health problems, such as diabetes, heart failure, etc., to help stem the
escalating health care costs in our nation.
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